Jyong Biotech (MENS) Competitors $36.90 -3.51 (-8.69%) As of 08/13/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsSEC FilingsTrendsBuy This Stock MENS vs. LEGN, ELAN, RVMD, RGC, RYTM, NUVL, AXSM, CRSP, LNTH, and ADMAShould you be buying Jyong Biotech stock or one of its competitors? The main competitors of Jyong Biotech include Legend Biotech (LEGN), Elanco Animal Health (ELAN), Revolution Medicines (RVMD), Regencell Bioscience (RGC), Rhythm Pharmaceuticals (RYTM), Nuvalent (NUVL), Axsome Therapeutics (AXSM), CRISPR Therapeutics (CRSP), Lantheus (LNTH), and ADMA Biologics (ADMA). These companies are all part of the "pharmaceutical products" industry. Jyong Biotech vs. Its Competitors Legend Biotech Elanco Animal Health Revolution Medicines Regencell Bioscience Rhythm Pharmaceuticals Nuvalent Axsome Therapeutics CRISPR Therapeutics Lantheus ADMA Biologics Legend Biotech (NASDAQ:LEGN) and Jyong Biotech (NASDAQ:MENS) are both mid-cap pharmaceutical products companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, profitability, institutional ownership, valuation, earnings, dividends and media sentiment. Do insiders & institutionals believe in LEGN or MENS? 70.9% of Legend Biotech shares are owned by institutional investors. 0.0% of Legend Biotech shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. Do analysts recommend LEGN or MENS? Legend Biotech presently has a consensus price target of $72.38, indicating a potential upside of 95.98%. Given Legend Biotech's stronger consensus rating and higher possible upside, research analysts clearly believe Legend Biotech is more favorable than Jyong Biotech.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Legend Biotech 0 Sell rating(s) 1 Hold rating(s) 8 Buy rating(s) 1 Strong Buy rating(s) 3.00Jyong Biotech 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Is LEGN or MENS more profitable? Jyong Biotech has a net margin of 0.00% compared to Legend Biotech's net margin of -40.83%. Jyong Biotech's return on equity of 0.00% beat Legend Biotech's return on equity.Company Net Margins Return on Equity Return on Assets Legend Biotech-40.83% -32.00% -20.07% Jyong Biotech N/A N/A N/A Which has better earnings and valuation, LEGN or MENS? Jyong Biotech has lower revenue, but higher earnings than Legend Biotech. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioLegend Biotech$796.84M8.52-$177.03M-$0.88-41.97Jyong BiotechN/AN/AN/AN/AN/A Does the media refer more to LEGN or MENS? In the previous week, Legend Biotech had 16 more articles in the media than Jyong Biotech. MarketBeat recorded 25 mentions for Legend Biotech and 9 mentions for Jyong Biotech. Legend Biotech's average media sentiment score of 0.45 beat Jyong Biotech's score of 0.34 indicating that Legend Biotech is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Legend Biotech 5 Very Positive mention(s) 2 Positive mention(s) 12 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Jyong Biotech 0 Very Positive mention(s) 1 Positive mention(s) 7 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral SummaryLegend Biotech beats Jyong Biotech on 9 of the 12 factors compared between the two stocks. Get Jyong Biotech News Delivered to You Automatically Sign up to receive the latest news and ratings for MENS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding MENS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MENS vs. The Competition Export to ExcelMetricJyong BiotechPharmaceutical Preparations IndustryManufacturing SectorNASDAQ ExchangeMarket Cap$3.07B$816.05M$2.54B$9.82BDividend YieldN/A4.84%2.56%4.11%P/E RatioN/A1.2022.2326.03Price / SalesN/A36.5794.66104.73Price / CashN/A19.5624.0558.93Price / BookN/A6.5834.776.06Net IncomeN/A-$4.11M$31.01M$265.11M7 Day Performance7.83%4.20%1.26%3.38%1 Month Performance217.83%-0.32%1.41%2.28%1 Year PerformanceN/A20.22%31.17%29.67% Jyong Biotech Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MENSJyong BiotechN/A$36.90-8.7%N/AN/A$3.07BN/A0.0031News CoverageGap DownLEGNLegend Biotech3.7626 of 5 stars$38.45-0.9%$73.33+90.7%-35.3%$7.07B$728.30M-65.172,609Trending NewsEarnings ReportAnalyst ForecastELANElanco Animal Health3.3769 of 5 stars$14.07+2.1%$16.17+14.9%+27.9%$6.99B$4.43B19.029,000Trending NewsEarnings ReportAnalyst ForecastAnalyst RevisionRVMDRevolution Medicines3.9896 of 5 stars$37.18+1.5%$68.91+85.3%-16.2%$6.93BN/A-9.30250Analyst RevisionRGCRegencell Bioscience0.1753 of 5 stars$13.76+6.1%N/AN/A$6.80BN/A0.0010Positive NewsRYTMRhythm Pharmaceuticals3.5899 of 5 stars$90.24+2.2%$91.93+1.9%+112.9%$5.74B$136.86M-32.11140News CoveragePositive NewsInsider TradeAnalyst RevisionNUVLNuvalent2.9504 of 5 stars$78.35+0.8%$119.60+52.6%+9.5%$5.58BN/A-17.8540Earnings ReportAnalyst RevisionAXSMAxsome Therapeutics4.84 of 5 stars$106.54+3.4%$172.33+61.8%+28.9%$5.25B$432.16M-18.46380CRSPCRISPR Therapeutics2.9158 of 5 stars$59.59+6.2%$70.07+17.6%+20.0%$5.15B$37.31M-13.18460Analyst RevisionLNTHLantheus4.8618 of 5 stars$71.46+1.3%$131.20+83.6%-44.8%$4.94B$1.53B20.30700Analyst ForecastADMAADMA Biologics4.3042 of 5 stars$19.91+3.0%$27.67+39.0%-0.4%$4.75B$426.45M23.42530 Related Companies and Tools Related Companies LEGN Alternatives ELAN Alternatives RVMD Alternatives RGC Alternatives RYTM Alternatives NUVL Alternatives AXSM Alternatives CRSP Alternatives LNTH Alternatives ADMA Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:MENS) was last updated on 8/14/2025 by MarketBeat.com Staff From Our PartnersHIDDEN IN THE BOOK OF GENESIS…“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredGet This Stock NowThis company is the lifeblood of AI data centers, yet almost no one has caught up with the story. Their hardwa...InvestorPlace | SponsoredWhen the levee breaksThe U.S. Treasury just confirmed it plans to borrow $1.01 trillion this quarter—nearly double what was project...Porter & Company | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredUtah’s New Oil FindThe Real Reason 218,000 Acres Just Vanished The government just quietly leased 218,000 acres in the middle ...Stansberry Research | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredNational 'Stock Market Reset' Coming September 30 (New WH Order)Crash Coming Sept 30? Analysts Warn of New Crisis A new problem on the U.S. power grid is putting millions ...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Jyong Biotech Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Jyong Biotech With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access